Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides


Published in:
Investigative ophthalmology & visual science

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2017 the authors. This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides

Felicity de Cogan,1 Lisa J. Hill,1 Aisling Lynch,2 Peter J. Morgan-Warren,1 Judith Lechner,2 Matthew R. Berwick,3 Anna F. A. Peacock,3 Mei Chen,2 Robert A. H. Scott,4 Heping Xu,2 and Ann Logan1

1Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom
2Centre for Experimental Medicine, Queen’s University Belfast, Belfast, United Kingdom
3School of Chemistry, University of Birmingham, Birmingham, United Kingdom
4Moorfields Eye Hospital Dubai, Dubai, United Arab Emirates

Correspondence: Felicity de Cogan, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, Vincent Drive, University of Birmingham, Birmingham, B15 2TT, United Kingdom; f.d.decogan@bham.ac.uk.

Submitted: June 6, 2016
Accepted: March 26, 2017

Purpose. To evaluate the efficacy of anti-VEGF agents for treating choroidal neovascularization (CNV) when delivered topically using novel cell-penetrating peptides (CPPs) compared with delivery by intravitreal (ivit) injection.

Methods. CPP toxicity was investigated in cell cultures. Ivit concentrations of ranibizumab and bevacizumab after topical administration were measured using ELISA. The biological efficacy of topical anti-VEGF + CPP complexes was compared with ivit anti-VEGF injections using an established model of CNV.

Results. CPPs were nontoxic in vitro. In vivo, after topical eye drop delivery, CPPs were present in the rat anterior chamber within 6 minutes. A single application of CPP + bevacizumab eye drop delivered clinically relevant concentrations of bevacizumab to the posterior chamber of the rat eye in vivo. Similarly, clinically relevant levels of CPP + ranibizumab and CPP + bevacizumab were detected in the porcine vitreous and retina ex vivo. In an established model of CNV, mice treated with either a single ivit injection of anti-VEGF twice daily CPP + anti-VEGF eye drops or daily dexamethasone gavage for 10 days all had significantly reduced areas of CNV when compared with lasered eyes without treatment.

Conclusions. CPPs are nontoxic to ocular cells and can be used to deliver therapeutically relevant doses of ranibizumab and bevacizumab by eye drop to the posterior segment of mouse, rat, and pig eyes. The CPP + anti-VEGF drug complexes were cleared from the retina within 24 hours, suggesting a daily eye drop dosing regimen. Daily, topical delivery of anti-VEGF with CPP was as efficacious as a single ivit injection of anti-VEGF in reducing areas of CNV in vivo.

Keywords: ocular drug delivery, cell-penetrating peptides, delivery of ranibizumab

In neovascular AMD (nAMD), VEGF stimulates growth of blood vessels from the choroidal vasculature through damaged Bruch’s membrane and into the retina. This leads to compromised retinal function and ultimately retinal damage, a condition for which anti-VEGF treatments are well established.1,2 To attenuate the progressive visual loss, anti-VEGF drugs are injected directly into the posterior segment of the eye, which arrests the dysregulated vascularization process.3 Although anti-VEGF drugs are extremely successful treatments for these vascular diseases, their repeated delivery by intravitreal (ivit) injection is very stressful to patients, costly to administer, and associated with significant complications, including retinal detachment, subconjunctival hemorrhage, uveitis, and endophthalmitis,5,4 all of which lead to poor patient compliance.3 Therefore, there is an urgent and unmet need for an alternative and less invasive drug-delivery route.5,6

Cell-penetrating peptides (CPPs) have been investigated as a potential method of drug delivery since the discovery of the protein transduction domain in the HIV-1 tat peptide in 1988.7,8 The internalization mechanism of these transduction peptide-containing proteins into cells has not been fully elucidated, with conflicting evidence for both active and passive processes.10–13 Although short-sequence peptides have been effectively used as chaperone agents to enhance the delivery of small molecule therapeutics to retina cells following subretinal injection,14 there is little evidence demonstrating their utility as chaperones for large drug molecules aiding their delivery to posterior segment tissues following topical application to the cornea. Once proven, this route of drug delivery would provide an alternative to the ivit injections used in nAMD clinics.

Delivery of large and small drug molecules into the eye by topical administration is a major challenge due to the unique anatomy and physiology of the eye.15 The various layers of the cornea, conjunctiva, sclera, and retina, along with the vascular blood-aqueous and blood-retinal barriers, create formidable static obstacles to drug penetration.16 Dynamic impediments to drug delivery include the choroidal and conjunctival blood flow, lymphatic clearance, efflux pumps, and tear dilution.17 These barriers combine to resist ocular drug delivery, especially to tissues in the posterior segment. Virtually all currently used eye drop formulations deliver their active agent (usually a small
molecule drug) through the cornea, sclera, and conjunctiva tissues by passive diffusion down the concentration gradient, thereby accessing the anterior segment, with a small minority of drugs also reaching the posterior segment in therapeutically relevant concentrations.2,8,19

The therapeutic half-life of a drug is determined by its potency, local titers, and bioavailability. Once inside the eye, drugs are eliminated anteriorly via the aqueous outflow portals or posteriorly through permeation of the blood-retinal barrier.20 Retinal delivery of clinically relevant quantities of large drugs, like antibodies, by repeated topical administration to the cornea has not yet been achieved. Large, negatively charged biopharmaceutical macromolecules, such as ranibizumab (Lucentis; Pharmaceuticals UK, Camberley, UK) (48 kD) and bevacizumab (Avastin; Genentech, San Francisco, CA, USA) (149 kD), are administered as repeated ivit injections to access retinal tissues.1,21 However, drug administration through this route is invasive and carries the risk of significant complications, giving a relatively high cost-to-benefit ratio.22

Oligoarginine CPPs of varying lengths have previously been used to aid drug delivery. For example, protein-peptide complexes have been formed from intermolecular interactions between oligoarginine and insulin proteins. These complexes have cell-penetrating properties and are bioactive so that, for example, peptides such as HWSYLPRRRRRRK deliver functional insulin across the gut epithelium both in vitro and in vivo.23 Similarly, oligoarginine CPPs (RRRRRRR), covalently linked to the topical anti-inflammatory drug cyclosorine A, have enhanced drug penetration of the stratum corneae of the skin to access the underlying epidermis.24

The aim of this study was to assess the potential for CPPs as chaperones within a topical ocular drug-delivery platform for the passage of therapeutic titers of high molecular weight VEGF antagonists to the posterior segment of the eye. Utilization of novel CPPs as ocular drug-delivery agents would facilitate clinical administration of large biopharmaceuticals, such as ranibizumab or bevacizumab, in the form of an eye drop. The development of this eye drop delivery platform will have wide-reaching implications for improved patient care, by reducing the side effects and treatment costs associated with both current clinically effective drugs and novel candidate drugs. Here, we have evaluated CPP-mediated eye drop delivery of anti-VEGF antibodies in rodent and porcine models to determine dose delivery and pharmacokinetics. We also have used an established in vivo rodent model of choroidal neovascularization (CNV) to compare the efficacy of anti-VEGF drugs when delivered topically with CPPs or by intravitreal injection.

**Materials and Methods**

**Animal Experiments**

All animal procedures were performed under license in accordance with the UK Home Office Animals Scientific Procedures Act 1986 and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

**Synthesis of CPPs**

CPP (5(6)-carboxyfluorescein-RRRRR-COOH) synthesis was performed on a 1-mmol scale on preloaded Fmoc-Nw-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)-L-arginine Wang resin (Sigma-Aldrich, Poole, UK) (loading rate 0.62 mmol per g)3 using standard Fmoc-amino acid solid-state peptide synthesis protocols. The initial Fmoc group was removed by deprotection with 20% piperidine in N,N-dimethylformamide (DMF) (3 × 20 minutes), followed by coupling with Fmoc-Nw-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)-L-arginine in the presence of O-(6-chlorobenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HCTU), N,N-diisopropylpropylthylamine (DIPEA), and DMF in a 1:5:5:10 molar ratio. The reaction was agitated at room temperature for 8 hours, and some of the resin was tested for reaction completion using the ninhydrin test following standard protocols.25 The coupling and deprotection steps were repeated until the peptide sequence reached a total of six arginine residues. The final Fmoc group was removed, the resin washed with DMF and dichloromethane (DCM), and the free N-terminus was coupled with 5(6)-carboxyfluorescein in the presence of HCTU and DIPEA in a 1:5:5:10 molar ratio in DCM for 8 hours, to give an unbuilt fluorescent tag. After washes with DME, DCM, and diethyl ether, the resin was air dried for 1 hour. The peptide was cleaved from the resin using trifluoroacetic acid (TFA) (27 mL), thioanisole (1.5 mL), 1,2-ethanedithiol (0.9 mL), and anisole (0.6 mL) under N2 with agitation in the dark for 3 hours, with simultaneous removal of side-chain protecting groups. Resin was removed by filtration and the crude peptide precipitated out of solution in cold diethyl ether and storage at −20°C for 8 hours. The precipitate was isolated by centrifugation at 2164g for 10 minutes and removal of the diethyl ether. The peptide was purified by preparative reversed-phase HPLC on a Phenomenex Luna C12 column (250 × 21.2 C12 [2] 10-μm Jupiter Proteo 90-A Axia Packed [Phenomenex, Macclesfield, UK]) with a solvent mixture altered with a linear gradient from 0.1% TFA in water to 0.1% TFA in CH3CN over 40 minutes. The isolated peptide was lyophilized to yield a yellow solid (258 mg, 19.6% yield at 97% purity), which was identified by electrospray ionization mass spectrometry. Stock solutions of the peptide were prepared in sterile PBS and stored at 4°C until use.

**CPP-Therapeutic Complex Formation**

CPPs (5 mg) were dissolved in stock solutions of bevacizumab (25 mg/mL; Roche Pharmaceuticals, Welwyn Garden City, UK) or ranibizumab (10 mg/mL; Novartis Pharmaceuticals UK). The solution was vortexed for 10 seconds and stored at 4°C until use.

**Circular Dichroism Analysis of CPP + Drug Complexes**

Circular dichroism (CD) was used to characterize the effect of concentration on CPP + bevacizumab complex formation. CD spectra were recorded in 1-mm pathlength quartz cuvettes on a Jasco J-715 spectropolarimeter (Jasco UK, Great Dunmow, UK).26 The stock solution of bevacizumab (125 μg/mL) was read at 200 to 300 nm. A stock solution of CPP was prepared at 1000 μg and diluted into the bevacizumab solution. The observed ellipticity was converted to molar ellipticity.

**In Vitro Cytotoxicity Assays**

**Primary Adult Rat Retinal Cell Cultures.** Adult rats (Sprague-Dawley; Charles River, Kent, UK) were killed by CO2 overdose and their eyes removed and the neural retinæ dissociated into single cells by using a papain dissociation kit, in accordance with the manufacturer’s instructions (Worthington Biochemicals, Lakewood, NJ, USA). Mixed retinal cells, containing retinal ganglion cells (RGCs), were seeded at a density of 125,000 cells/well in 8-well chamber slides (BD Biosciences, Erembodegem, Belgium), precoated with polyd-lysine and laminin (20 μg/mL) in 500-μL well Neurobasal-A supplemented with B27 supplement and gentamicin (all from...
In Vitro Anterior Segment Imaging of CPP Passage Into the Rat Eye

Male Sprague-Dawley rats (200 g) (Charles River) were anesthetized by using 5% isoflurane (National Vet Supplies, Stoke, UK) under Home Office Licence 30/2720. The rats had a 20-μL CPP eye drop applied to the cornea and the eyes were imaged using a Spectralis Anterior Segment Module on the Heidelberg Spectralis optical coherence tomography (OCT) system (Heidelberg Engineering, Heidelberg, Germany) every 30 seconds for 10 minutes.

In Vivo CPP Delivery of Anti-VEGF Into the Vitreous of Rat Eyes and the Time Course of Anti-VEGF Clearance From the Vitreous and Retina

Under Home Office Licence 30/2720, adult male Sprague-Dawley rats (200 g) (Charles River) had a single 20-μL eye drop containing CPP (5 μg/μL), CPP (5 μg/μL) + bevacizumab (25 μg/μL), bevacizumab (25 μg/μL), or PBS applied topically to the corneal surface. The rats were rehoused and observed for well-being for 30 minutes before killing by using rising levels of CO₂ and dissection of the ocular tissues. In a second study, groups of rats were killed by raising levels of CO₂ at 20, 40, and 60 minutes plus 2, 4, and 24 hours after anti-VEGF drug delivery (τ = four rats per group), eyes were removed, and the vitreous and retinae were harvested together. The combined tissues were freeze-thawed and homogenized together in 110 μL sterile PBS. The level of bevacizumab in the retinal homogenate was measured by using a Protein Detection ELISA kit (KPL, Gaithersburg, MD, USA) with an anti-human antibody (309-001-003; Jackson Immuno Research Laboratory, West Grove, PA, USA). Briefly, high-affinity plates (Sigma-Aldrich) were coated with 0.1 μg/mL anti-human antibody for 1 hour and the ELISA was then carried out according to manufacturer’s instructions.

Ex Vivo Anti-VEGF Drug Delivery Into Porcine Eyes

Adult porcine eyes were obtained from a local slaughterhouse, stored on ice, and used within 5 hours of animal death. The eyes were irrigated with PBS and then had a 60-μL eye drop with and without drug applied to the cornea. After 45 minutes’ incubation period at room temperature, eyes were washed three times with PBS and the vitreous and retina were removed. Vitreous was freeze-thawed and homogenized, and the vitreous and retina were removed. Vitreous was freeze-thawed and homogenized, and the vitreous and retina were removed. Vitreous was freeze-thawed and homogenized, and the vitreous and retina were removed.
In Vivo Efficacy of Anti-VEGF Agent in a Mouse Model of CNV

Wild-type (WT) C57BL/6J mice (Harlan Laboratories, Derby, UK) were maintained within the Biological Research Unit at Queen’s University Belfast and the CNV study was performed at this site in accordance with UK Home Office (Animals [Scientific Procedures] Act, 1986) guidelines and the experimental protocols were approved by the University Ethics Committee. To create CNV, mice were anesthetized by injection of Rompun (xylazine) (2% wt/vol; Bayer, Newbury, UK) and Ketaset (100 mg/mL; Fort Dodge Animal Health, Ltd., Hampshire, UK) and rupture of Bruch’s membrane–choroid was achieved by laser photocoagulation (Haag Streit BM 900 Silt Lamp and Argon laser, Haag Streit, Harlow, UK) using CNV laser burns of 100-μm spot size (0.05-second duration, 250 mW) approximately two disc-diameters away from the optic disc. Mice were randomly allocated into seven groups (Fig. 1): (1) (n = 6) received CNV laser burn only; (2) (n = 4) received CNV laser burn and treatment with 0.5 mg/kg/d for 10 days of dexamethasone delivered systemically through gavaging; (3) (n = 6) received CNV laser burn and treatment with a single 2-μL intravitreal injection of 200 ng/μL of anti-VEGF (R&D Systems, Abingdon, UK); (4) (n = 4) received CNV laser burn and treatment with a single 5-μL eye drop containing CPP 25 μg/5 μL + anti-VEGF 1.8 μg/5 μL administered twice daily for 10 days; (5) (n = 6) received CNV laser burn and treatment with a single 5-μL eye drop containing PBS + 1.8 μg/5 μL of anti-VEGF administered twice daily for 10 days; (6) (n = 6) received CNV laser burn and treatment with a single 5-μL eye drop containing CPP 25 μg/5 μL only administered twice daily for 10 days; and (7) (n = 6) received CNV laser burn and treatment with a single 5-μL PBS eye drop administered twice daily for 10 days. Just before killing the mice on day 10, confocal scanning laser ophthalmoscopy (Heidelberg Engineering) was carried out under anesthesia to obtain retinal angiography data immediately after intravenous injection of 100 μL 10% sodium fluorescein.

Mice were killed by cervical dislocation and the eyes were immediately dissected and placed in 2% PFA (Sigma-Aldrich) in PBS for 2 hours. Following this, the PFA was removed and eyes were stored in PBS at 4°C for 5 days before being dissected. For dissections, the RPE/choriocapillaris/sclera was removed in its entirety and placed in PBS as a floating structure. The RPE/choriocapillaris/sclera was washed again in PBS before permeabilization in 1% Triton X-100 (Sigma-Aldrich) for 1.5 hours at room tempera-

Figure 1. Experimental design to assess in vivo efficacy of anti-VEGF in a mouse model of CNV.
deg-cm²/dmol. This peak was enhanced to −2694.9 deg-cm²/dmol when 150 µg CPP was added to bevacizumab (1 mL), to −2689.4 deg-cm²/dmol with 300 µg CPP and to 2704.7 deg-cm²/dmol with 500 µg CPP. This indicates that CPPs form a complex with bevacizumab, and that increasing the relative concentration of CPP above 150 µg does not significantly alter the complex structure.

CPPs Are Nontoxic for Rat Retinal, Human ARPE-19 Cells, and Human Corneal Fibroblasts

The CPPs were tested for cytotoxicity against a range of ocular cells before in vivo testing via continuous exposure to CPP for 3 days in culture. In primary mixed retinal cultures from adult rats, the numbers of βIII-tubulin + RGC surviving after treatment with CPP at concentrations of 0.1 µg/mL, 1 µg/mL, 10 µg/mL, and 100 µg/mL were not significantly different from that in the PBS control (Fig. 3a). Similarly, in human ARPE-19 cells (Fig. 3b) cell numbers at the concentrations of 0.1 µg/mL, 1 µg/mL, 10 µg/mL, and 100 µg/mL CPP were not significantly different from that in the PBS control. There was also no effect on numbers of primary human corneal fibroblasts (Fig. 3c) surviving after 3 days of treatment with CPP at any concentration tested compared to the PBS control. These results indicate that the CPPs were not cytotoxic to ocular cells at the concentrations tested after 3 days in culture.

Eye Drop Formulations of CPP-Drug Complexes Deliver Drugs Rapidly Across the Cornea to the Anterior and Posterior Segments of the Rat Eye

Fluorescently tagged CPPs (20 µL of 5 µg/µL) were applied topically to the cornea of an anesthetized rat and OCT images were taken every 30 seconds. Fluorescent CPPs were observed in solution on the surface of the cornea at 0 minutes and were present within the anterior chamber by 6 minutes (Fig. 4A). Further eye drop studies quantified the amount of anti-VEGF antibody the CPP delivered across the cornea, to the anterior and posterior segments, and into retinal tissue (Fig. 4B). When a 20-µL eye drop of bevacizumab (25 µg/µL) complexed with CPP (5 µg/µL) was applied to the cornea, 1.06 ± 0.35 µg/mL of bevacizumab was detected by ELISA within tissue homogenates after 30 minutes. This represented 0.2% of the delivered payload. This level was significantly higher (P < 0.001) than that seen in all controls. Clearance of bevacizumab from the retina following delivery by topical application was then established by examining retinal levels of bevacizumab over time (Fig. 4C). This showed that 0.68 ± 0.26 µg/mL bevacizumab was detected within the tissue homogenates at 20 minutes after topical administration, with levels increasing to 1.65 ± 0.26 µg/mL at 40 minutes, followed by decreasing levels, with 0.4 ± 0.22 µg/mL detectable at 4 hours and 0.007 ± 0.22 µg/mL at 24 hours after topical application. This shows a clearance of bevacizumab from the rodent retina by 24 hours, suggesting a daily dosing regimen would be required to sustain therapeutic levels by eye drop drug delivery in disease model studies and also implies the need for daily dosing in humans.

CPP-Drug Complexes Access Retinal Tissues After Eye Drop Delivery to the Pig Eye

Eye drops of 20 µL containing ranibizumab (10 µg/µL) complexed with CPP or bevacizumab (25 µg/µL) complexed with CPP, or appropriate controls, were applied topically to porcine cornea, and after 45 minutes vitreous and retinae were dissected and the levels of human IgG measured by ELISA (Figs. 5a, 5b). The levels of human IgG measured indicate that, when drugs were complexed with CPP, topical delivery achieved 17.09 ± 4.68 µg/mL of ranibizumab and of 10.68 ± 3.57 µg/mL of bevacizumab in the total vitreous. This represented significantly higher (P < 0.001) levels than those seen in control animals, treated with eye drops containing either uncomplexed ranibizumab, uncomplexed bevacizumab eye, CPP-alone, or PBS-alone. Similarly, 0.10 ± 0.03 µg per retina of bevacizumab was detected in the retina after application of CPP + bevacizumab complex eye drops. This was also significantly higher than levels in the control groups (P < 0.005).
Eye Drop CPP–Anti-VEGF Complexes Attenuate Neovascularization in a Mouse Model of CNV

The bioefficacy of anti-VEGF when delivered topically complexed to CPP was determined in a mouse model of CNV. Fluorescein angiography (FA) and infrared imaging (IR) at 10 days in all groups demonstrated that eye drop delivery of CPP + anti-VEGF complexes considerably reduced the size of the laser-induced CNV lesion, characterized by an area of hyperfluorescence surrounding a core of hypofluorescence (Fig. 6). This lesion denotes an area of high neovascularization that leads to fluorescein leakage and, therefore, the increased fluorescence levels observed. When the size of the untreated CNV fluorescent halos were compared with those in the lasered treatment group receiving eye drops containing uncomplexed anti-VEGF or the three negative control groups, no differences were apparent. By contrast, smaller CNV fluorescent halos were measured in the two positive control groups receiving daily systemic dexamethasone by gavage or a single anti-VEGF ivit injection. RPE/choroidal flatmount...
immunohistochemistry of collagen IV and isolectin B4 (as markers of extracellular matrix and endothelial cells, respectively) allowed the areas of scar and neovascularization to be measured and compared (Fig. 7). This showed that the animals with CNV without further treatment showed a lesion area of collagen IV and isolectin staining of $176,195 \pm 63,396 \text{ mm}^2$. Lesion areas were reduced to $49,898 \pm 10,207 \text{ mm}^2$ in animals that received daily gavage steroid treatment. A reduction to $49,817 \pm 11,015 \text{ mm}^2$ was also seen in eyes receiving a single intravitreal anti-VEGF injection. When anti-VEGF was delivered topically complexed to CPP, a similar reduction in lesion area was observed to $48,388 \pm 5521 \text{ mm}^2$. The lesion sizes in

![Figure 4](http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936209/)
all three treatment groups were significantly lower than those in CNV eyes that received no treatment ($P < 0.001$), with no significant difference among the three treatment groups.

Lesion areas in the negative control groups of CPP-only eye drops (89,540 ± 14,706 $\mu$m²), anti-VEGF-only drops (112,802 ± 18,855 $\mu$m²), and PBS eye drops (105,714 ± 25,149 $\mu$m²) were all significantly higher than those in animals that received CPP delivered anti-VEGF ($P < 0.001$), with no significant difference between these negative controls and those animals that received no treatment. These data show that daily topical administration of the CPP complexed with anti-VEGF was as efficacious as the standard single ivit injection of anti-VEGF.

**DISCUSSION**

Anti-VEGF agents are a well-established treatment for nAMD; however, the side effects from delivery by ivit injection represent a significant problem. Accordingly, this study investigated the use of CPP as a novel topical delivery vehicle for anti-VEGF agents to the posterior segment, negating the need for invasive ivit injections. This study demonstrates that CPP can successfully deliver topically applied anti-VEGF drugs into mouse, rat, and pig eyes, and showed bioactivity of the topically delivered drug in a relevant disease model that was equivalent to other AMD drug-delivery methods.

The use of CPPs as drug-penetration enhancers is well described in the literature. For example, CPPs can be covalently coupled to psoriasis drugs to enhance transdermal delivery. Although this study further illustrates the clinical potential of penetration enhancers, CPP platform technologies have not previously been established, as each drug has been delivered using a novel CPP attachment method. For example, previous work by Johnson et al. reports the delivery of green fluorescent protein to the cornea after topical application and to the retina after ivit injection. However, this work relied on
grafting the CPP to the therapeutic load and (for posterior segment delivery) an injection either intravitreally or subretinally. In contrast, here we have exploited simple charge-based interactions between the CPP and the therapeutic to formulate drug complexes that are decorated by the CPP. This enhances drug passage across tissue barriers, both into cells and between cells, and also ensures that drug bioefficacy is not compromised by the permanent attachment of the CPP unit onto the drug molecule. Accordingly, current drug stockpiles and methods of manufacture can be used in preparing the CPP-drug complexes.

In contrast, here we have exploited simple charge-based interactions between the CPP and the therapeutic to formulate drug complexes that are decorated by the CPP. This enhances drug passage across tissue barriers, both into cells and between cells, and also ensures that drug bioefficacy is not compromised by the permanent attachment of the CPP unit onto the drug molecule. Accordingly, current drug stockpiles and methods of manufacture can be used in preparing the CPP-drug complexes.

The CPP concentration estimated in different anatomical compartments through the eye after eye drop delivery informed the in vitro investigations into CPP toxicity for ocular cells after 3 days in culture. Examination of the literature shows that poly-arginine–based CPPs have been tested extensively against many cell types, with reports conflicting whether CPPs inflict toxic effects on cells. Here, topical delivery by eye drop delivered 5 mg/mL CPP onto the cornea,
with 85 μg/mL calculated to be present in the posterior segment after 30 minutes, based on the detected presence of the anti-VEGF. These values were then used to provide the concentration range to test toxicity on cultured rodent and human ocular cells. The CPPs used in this study showed no apparent toxicity to any ocular cell type tested between 0.1 and 100 μg/mL.

The speed of drug penetration and delivery to the retina after application to the corneal surface of the eye is vital, as drugs in aqueous solution are cleared from the tear film in 15 to 30 seconds, so it was important to measure the rate of transfer of CPP + bevacizumab and CPP + ranibizumab complexes across the cornea. OCT of the rat eye over 10 minutes showed that fluorescent CPP complexes were

**Figure 7.** Immunohistochemical staining of retinal CNV lesions confirmed no difference between ivit anti-VEGF and CPP + anti-VEGF eye drops. (A) Immunohistochemical staining of the neovascularization in CNV lesions (collagen IV: red, isolectin B4: green) confirmed that, compared with untreated CNV-only retinae, vascular lesions were smaller after treatment with CPP + anti-VEGF eye drops, ivit injection of anti-VEGF, and systemic dexamethasone. Anti-VEGF PBS (experimental and statistical control), and unloaded CPP eye drops did not affect CNV size (scale bar: 100 μm). (B) Quantitation of areas of isolectin B4 + CNV lesions. Compared with untreated controls, CNV lesions in mice receiving CPP + anti-VEGF eye drops, ivit injection of anti-VEGF, and systemic dexamethasone were all similarly reduced (n = 6, **P < 0.001), whereas CNV lesion sizes were unchanged after topical treatment with anti-VEGF, PBS, and unloaded CPP eye drops.
observed in the anterior chamber by 6 minutes. ELISA at later time points showed that levels of bevacizumab delivered by a CPP complex to retinal tissue increased over the first hour, to reach a maximum of 1 μg, representing 0.2% of the topically applied pay load. Retinal levels decreased over the following 24 hours as the drug was cleared from the tissue. Although the drug was still detectable in retinal tissues at very low levels after 24 hours. These results demonstrate the ability of CPP to form complexes with humanized antibody drugs and aid delivery across tissue barriers to access posterior segment target tissues in the physiologically relevant μg/mL concentration range indicated in literature data.17–18 These studies were carried out in rodent eyes in which the ocular volume and delivery path length do not allow comparisons with the human eye. For example, the average thickness of the human cornea measures 555 ± 20 μm in the center compared with 118 ± 8 μm of the central mouse cornea.49 Therefore, ex vivo studies were carried out in porcine eyes that have a corneal thickness of 666 ± 123 μm, making them more comparable to a human eye.50 Similar titers of antibody were delivered to the porcine posterior segment, suggesting relevance of the delivery strategy to the human eye.

The in vivo rat and ex vivo porcine observations prompt two conclusions. First, that, after topical delivery complexed to CPPs, ranibizumab and bevacizumab can access retinal tissues from the vitreous in a similar manner to that after direct ivit injection. Second, a dosing regimen that is comparable to current clinical practice is relevant to this delivery route. The current “gold standard” dosing regimen in patients is monthly injections of 300 to 500 μg/eye ranibizumab or 100 to 300 μg/eye bevacizumab. Preclinical studies have shown that 0.5 days after a 500 μg/eye injection, detectable levels in the vitreous are approximately 200 μg/mL.42 Ranibizumab has a relatively short half-life in the vitreous of 4 days, with no detectable levels seen in preclinical trials 10 days after a single ivit injection.51 Our rat study also showed that the drug cleared from the vitreous over 24 hours, allowing inferences to be made for human vitreal clearance patterns.52 Clinical trials have demonstrated that, after ivit injection of 1500 μg/eye of bevacizumab, clearance from the aqueous humor leaves 33 μg/mL of drug at 1 day postinjection, dropping to less than 10 μg/mL by day 18.43 Human intravitreal concentrations of bevacizumab have been shown at 16 μg/mL at 2 days postinjection and 0.5 μg/mL at 4 weeks postinjection.44 This indicates a target delivery level to the human retina of between 1 and 200 μg/eye over 4 weeks. Therefore, in the porcine study reported here, the CPP + anti-VEGF ratio was optimized to effect drug delivery in this therapeutic range. The delivery of 10 to 20 μg/mL to the posterior segment achieved in the ex vivo porcine study is within the established therapeutic range for humans (10–200 μg/mL). Although low levels of IgG were detected in the control groups, this was observed due to low levels of cross reactivity of the antibody with porcine IgG already observed by Davis et al.53 The topical CPP-mediated drug delivery showed drug clearance over 24 hours, with most of the anti-VEGF cleared from the ocular tissues by 4 hours. This indicates the potential for twice/thrice daily eye drops to give a repeated, sustained dose that would maintain therapeutic levels of drug in the eye for sustained periods. Future studies will determine systemic levels of the delivered anti-VEGF reflecting systemic clearance of the drug from the eye.

Once the dosing regimen and therapeutic levels achievable were determined, the CPP + anti-VEGF eye drop was tested in an established murine model of CNV to determine bioefficacy of the drug delivered using this route. It should be noted that the absence of a defined macula in mice and the laser trauma model used does not accurately mimic the complexity of the human pathology. This model is effectively a wound-healing reaction that follows an insult at the level of Bruch’s membrane and relies heavily on inflammation. In contrast in AMD, genetic susceptibility plays a major role in disease progression; hence, why steroids can be used for treatment in the mouse model but are ineffective in humans.46 However, the mouse laser model does allow assessment of the effects of anti-VEGF on neovascularization, an important component of AMD pathophysiology.

RPE/choroid flatmount immunohistochemistry of collagen IV and isoclit B4 (as markers of neovascularization and endothelial cells, respectively, that revealed the lesion area) supported the conclusions derived from in vivo imaging of fluorescein leakage from vessels. Animals that received daily dexamethasone gavage, a single ivit anti-VEGF injection, or twice-daily eye drops for 10 days containing CPP + anti-VEGF complexes all had significantly smaller areas of collagen and isoclit B4 staining, indicative of smaller CNV lesions when compared with the three negative control groups of PBS, CPP-alone, and anti-VEGF-alone eye drops. These results obtained with eye drop delivery of CPP-anti-VEGF accord well with the results of other published studies using the CNV model to demonstrate the efficacy of a range of anti-VEGF drugs that significantly reduce the area of choroidal neovascularization.47–50

In summary, these data indicate the utility of a novel noninvasive eye drop delivery mechanism for nAMD drugs. The CPP-drug eye drops have potential to significantly impact the treatment of nAMD by revolutionizing drug-delivery options. Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments. The CPP + drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.

**Conclusions**

We have demonstrated a novel platform eye drop technology for ocular drug delivery that is broadly applicable because it does not require chemical conjugation of the drug chaperone. Specifically, we have shown that CPPs have high penetrating capabilities for biological barriers in the eye with low toxicity and can deliver clinically relevant concentrations of anti-VEGF drugs, such as ranibizumab and bevacizumab, to the posterior segment of the eye. In particular, these CPPs have the capacity to noninvasively deliver therapeutics in bioactive form to anterior and posterior ocular segments to give outcomes comparable to intravitreally injected drugs. If the results were translated to human eyes, it would allow the topical delivery of a wide range of ocular drugs that currently can be delivered only by ivit or subconjunctival injections. This would reduce treatment costs, time in clinic, and harmful side effects, while allowing patient self-administration, so that new drug-delivery regimens can be better tolerated.

**Acknowledgments**

Supported by an ARVO fellowship. In vitro testing of the drug-delivery peptides was funded by the National Institute of Health Research, Surgical Reconstruction and Microbiology Research Centre, Birmingham. Some of the experiments were performed by Neuregenix Ltd., Birmingham, UK, that had no commercial interest in the study outcomes.

Disclosure: F. de Cogan, None; L.J. Hill, None; A. Lynch, None; P.J. Morgan-Warren, None; J. Lechner, None; M.R. Berwick, None; A.F.A. Peacock, None; M. Chen, None; R.A.H. Scott, None; H. Xu, None; A. Logan, None
References


